IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announces that the U. S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on […]
Tag: Endologix
Endologix Announces that Lucas Buchanan Joins Board of Directors
RVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Lucas Buchanan has been appointed to the Endologix Board of Directors. “We […]
Endologix Announces First Patients Treated with the DETOUR™ System, Advancing Treatment for Complex Peripheral Artery Disease
IRVINE, Calif.–(BUSINESS WIRE)–Endologix Inc. a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the first patients underwent Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR system, since FDA […]
Endologix Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting
The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOURTM System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the […]
Endologix Receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the DETOUR System […]
Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial
JAGUAR Study Evaluates ALTO® Compared to Other Commercially Available EVAR Devices IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the completion of the […]
Endologix Wins “Medical Device Engineering Breakthrough” Award in 7th Annual MedTech Breakthrough Awards Program
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today […]
Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)
The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device […]
Endologix Receives FDA Approval of PMA Supplement for AFX2 System
The AFX2 Endovascular AAA System integrates anatomical fixation with an advanced delivery system to facilitate treatment of patients with abdominal aortic aneurysm (AAA). IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company, dedicated to improving patients’ lives with […]
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, announced the 12-month results of the DETOUR 2 trial during a late-breaking clinical […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet